ZLAB
Zai Lab Limited
Price Chart
Latest Quote
$16.30
Current Price| Previous Close | $16.60 |
| Open | $16.24 |
| Day High | $16.44 |
| Day Low | $15.96 |
| Volume | 1,358,162 |
Stock Information
| Shares Outstanding | 110.59M |
| Total Debt | $219.36M |
| Cash Equivalents | $717.16M |
| Revenue | $441.63M |
| Net Income | $-206.81M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.80B |
| EPS (TTM) | $-1.90 |
| Exchange | NGM |
📊 Custom Metrics & Score
Score: 15/42| Debt to Equity | 0.18 |
| Debt to Earnings | 0.61 |
| Current Ratio | 3.51 |
| Quick Ratio | 2.90 |
| Avg Revenue Growth | 44.12% |
| Profit Margin | -64.44% |
| Return on Equity | -30.57% |
| Avg FCF Growth | -12.84% |
| FCF Yield | -15.33% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $16.30 | 1,383,031 |
| 2026-01-30 | $16.60 | 612,600 |
| 2026-01-29 | $17.25 | 599,600 |
| 2026-01-28 | $17.20 | 621,200 |
| 2026-01-27 | $17.05 | 999,800 |
| 2026-01-26 | $17.64 | 778,300 |
| 2026-01-23 | $18.33 | 306,600 |
| 2026-01-22 | $18.37 | 881,600 |
| 2026-01-21 | $18.84 | 733,300 |
| 2026-01-20 | $18.91 | 588,900 |
| 2026-01-16 | $18.58 | 516,000 |
| 2026-01-15 | $18.82 | 992,800 |
| 2026-01-14 | $19.61 | 1,035,500 |
| 2026-01-13 | $18.72 | 694,700 |
| 2026-01-12 | $18.39 | 628,300 |
| 2026-01-09 | $18.55 | 695,500 |
| 2026-01-08 | $18.50 | 1,463,900 |
| 2026-01-07 | $19.03 | 1,344,700 |
| 2026-01-06 | $18.20 | 714,000 |
| 2026-01-05 | $18.09 | 1,008,900 |
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
📰 Latest News
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform
Insider Monkey • 2026-01-30T07:07:28Z
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires • 2026-01-15T15:37:59ZIs Zai Lab (ZLAB) Pricing Reflect Its Potential After Multi‑Year Share Price Slump
Simply Wall St. • 2026-01-14T19:11:34Z
Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading
MT Newswires • 2026-01-14T15:36:04ZAsian Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading
MT Newswires • 2026-01-13T15:48:33ZAsian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
MT Newswires • 2026-01-12T15:42:41ZUBS Gives Zai Lab (ZLAB) a Buy Rating
Insider Monkey • 2026-01-09T08:16:50Z
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After AUGTYRO’s First NTRK Fusion Approval In China
Simply Wall St. • 2026-01-08T12:13:02Z
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
MT Newswires • 2026-01-07T15:43:35ZAsian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires • 2026-01-05T15:47:04ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $147,860,000 | $95,816,000 | $74,018,000 | $52,239,000 |
| Cost Of Revenue | $147,860,000 | $95,816,000 | $74,018,000 | $52,239,000 |
| Total Revenue | $398,988,000 | $266,719,000 | $215,040,000 | $144,312,000 |
| Operating Revenue | $425,229,000 | $298,911,000 | $236,377,000 | $190,387,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $2,254,000 | $0 | $0 | $0 |
| Total Expenses | $672,935,000 | $640,859,000 | $607,926,000 | $840,263,000 |
| Other Income Expense | $-18,007,000 | $-277,000 | $-64,761,000 | $-9,653,000 |
| Other Non Operating Income Expenses | $3,235,000 | $1,784,000 | $594,000 | $303,000 |
| Net Non Operating Interest Income Expense | $34,851,000 | $39,797,000 | $14,582,000 | $2,190,000 |
| Interest Expense Non Operating | $2,254,000 | $0 | $0 | $0 |
| Operating Expense | $525,075,000 | $545,043,000 | $533,908,000 | $788,024,000 |
| Other Operating Expenses | $-8,170,000 | $-2,433,000 | $-11,471,000 | $-4,113,000 |
| Selling And Marketing Expense | $123,783,000 | $108,219,000 | $61,512,000 | $71,255,000 |
| General And Administrative Expense | $174,958,000 | $173,389,000 | $197,459,000 | $147,576,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Net Interest Income | $34,851,000 | $39,797,000 | $14,582,000 | $2,190,000 |
| Interest Income | $37,105,000 | $39,797,000 | $14,582,000 | $2,190,000 |
| Normalized Income | $-241,966,000 | $-329,770,000 | $-386,883,000 | $-709,132,000 |
| Net Income From Continuing And Discontinued Operation | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Total Operating Income As Reported | $-282,117,000 | $-366,573,000 | $-404,357,000 | $-700,064,000 |
| Net Income Common Stockholders | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Net Income | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Net Income Including Noncontrolling Interests | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Net Income Continuous Operations | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $0 | $-221,000 | $-1,057,000 |
| Pretax Income | $-257,103,000 | $-334,620,000 | $-443,065,000 | $-703,414,000 |
| Special Income Charges | $0 | $10,000,000 | $0 | $0 |
| Earnings From Equity Interest | $-6,105,000 | $2,789,000 | $-8,952,000 | $-14,617,000 |
| Interest Income Non Operating | $37,105,000 | $39,797,000 | $14,582,000 | $2,190,000 |
| Operating Income | $-273,947,000 | $-374,140,000 | $-392,886,000 | $-695,951,000 |
| Gross Profit | $251,128,000 | $170,903,000 | $141,022,000 | $92,073,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.60 | $-3.50 | $-4.60 | $-7.58 |
| Basic EPS | $-2.60 | $-3.50 | $-4.60 | $-7.58 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-227,856,000 | $-320,741,000 | $-378,435,000 | $-694,125,000 |
| Total Unusual Items | $-15,137,000 | $-4,850,000 | $-56,403,000 | $4,661,000 |
| Total Unusual Items Excluding Goodwill | $-15,137,000 | $-4,850,000 | $-56,403,000 | $4,661,000 |
| Reconciled Depreciation | $11,856,000 | $9,029,000 | $8,227,000 | $6,487,000 |
| EBITDA (Bullshit earnings) | $-242,993,000 | $-325,591,000 | $-434,838,000 | $-689,464,000 |
| EBIT | $-254,849,000 | $-334,620,000 | $-443,065,000 | $-695,951,000 |
| Diluted Average Shares | $98,947,773 | $96,639,413 | $95,806,714 | $92,992,112 |
| Basic Average Shares | $98,947,773 | $96,639,413 | $95,806,714 | $92,992,112 |
| Diluted NI Availto Com Stockholders | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Ppe | $0 | $10,000,000 | $0 | $0 |
| Gain On Sale Of Security | $-15,137,000 | $-14,850,000 | $-56,403,000 | $4,661,000 |
| Research And Development | $234,504,000 | $265,868,000 | $286,408,000 | $573,306,000 |
| Selling General And Administration | $298,741,000 | $281,608,000 | $258,971,000 | $218,831,000 |
| Other Gand A | $123,783,000 | $22,507,000 | $35,414,000 | $22,901,000 |
| Salaries And Wages | $174,958,000 | $173,389,000 | $162,045,000 | $124,675,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $781,964,000 | $779,660,000 | $1,037,192,000 | $1,370,297,000 |
| Total Assets | $1,185,753,000 | $1,036,295,000 | $1,220,140,000 | $1,609,956,000 |
| Total Non Current Assets | $135,273,000 | $96,689,000 | $95,804,000 | $109,075,000 |
| Other Non Current Assets | $1,114,000 | $1,113,000 | $803,000 | $803,000 |
| Non Current Prepaid Assets | $1,284,000 | $1,209,000 | $1,396,000 | $870,000 |
| Non Current Accounts Receivable | $1,351,000 | - | - | $23,858,000 |
| Goodwill And Other Intangible Assets | $58,934,000 | $16,458,000 | $8,403,000 | $9,659,000 |
| Other Intangible Assets | $58,934,000 | $16,458,000 | $8,403,000 | $9,659,000 |
| Current Assets | $1,050,480,000 | $939,606,000 | $1,124,336,000 | $1,500,881,000 |
| Other Current Assets | $41,527,000 | $22,995,000 | $35,674,000 | $18,021,000 |
| Restricted Cash | $100,000,000 | $0 | - | - |
| Inventory | $39,875,000 | $44,827,000 | $31,621,000 | $18,951,000 |
| Receivables | $89,411,000 | $65,333,000 | $48,571,000 | $54,809,000 |
| Notes Receivable | $4,233,000 | $6,134,000 | $8,608,000 | $7,335,000 |
| Accounts Receivable | $85,178,000 | $59,199,000 | $39,963,000 | $47,474,000 |
| Allowance For Doubtful Accounts Receivable | $-25,000 | $-17,000 | $-11,000 | $-11,000 |
| Gross Accounts Receivable | $85,203,000 | $59,216,000 | $39,974,000 | $47,485,000 |
| Cash Cash Equivalents And Short Term Investments | $779,667,000 | $806,451,000 | $1,008,470,000 | $1,409,100,000 |
| Cash And Cash Equivalents | $449,667,000 | $790,151,000 | $1,008,470,000 | $964,100,000 |
| Cash Equivalents | $1,159,000 | $1,100,000 | $1,047,000 | $300,628,000 |
| Cash Financial | $448,508,000 | $789,051,000 | $1,007,423,000 | $663,472,000 |
| Prepaid Assets | - | - | - | $18,021,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $153,471,000 | $15,151,000 | $20,393,000 | $15,540,000 |
| Long Term Debt And Capital Lease Obligation | $13,712,000 | $8,047,000 | $13,343,000 | $9,613,000 |
| Current Debt And Capital Lease Obligation | $139,759,000 | $7,104,000 | $7,050,000 | $5,927,000 |
| Current Debt | $131,711,000 | - | - | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $344,855,000 | $240,177,000 | $174,545,000 | $230,000,000 |
| Total Non Current Liabilities Net Minority Interest | $45,470,000 | $37,110,000 | $34,703,000 | $37,099,000 |
| Other Non Current Liabilities | $325,000 | $325,000 | - | - |
| Non Current Deferred Liabilities | $31,433,000 | $28,738,000 | $21,360,000 | $27,486,000 |
| Current Liabilities | $299,385,000 | $203,067,000 | $139,842,000 | $192,901,000 |
| Other Current Liabilities | $6,352,000 | $5,353,000 | $4,054,000 | $4,421,000 |
| Payables And Accrued Expenses | $153,274,000 | $190,610,000 | $128,738,000 | $182,553,000 |
| Payables | $106,509,000 | $132,453,000 | $84,526,000 | $137,548,000 |
| Other Payable | $449,000 | $2,474,000 | $5,269,000 | $2,568,000 |
| Total Tax Payable | $5,154,000 | $16,988,000 | $13,283,000 | $8,817,000 |
| Accounts Payable | $100,906,000 | $112,991,000 | $65,974,000 | $126,163,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $840,898,000 | $796,118,000 | $1,045,595,000 | $1,379,956,000 |
| Total Equity Gross Minority Interest | $840,898,000 | $796,118,000 | $1,045,595,000 | $1,379,956,000 |
| Stockholders Equity | $840,898,000 | $796,118,000 | $1,045,595,000 | $1,379,956,000 |
| Gains Losses Not Affecting Retained Earnings | $50,515,000 | $37,626,000 | $25,685,000 | $-23,645,000 |
| Other Equity Adjustments | $50,515,000 | $37,626,000 | $25,685,000 | $-23,645,000 |
| Retained Earnings | $-2,453,083,000 | $-2,195,980,000 | $-1,861,360,000 | $-1,418,074,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $4,912,200 | $4,912,200 | $2,236,280 | $382,930 |
| Ordinary Shares Number | $1,077,702,540 | $972,239,070 | $960,219,570 | $954,981,050 |
| Share Issued | $1,082,614,740 | $977,151,270 | $962,455,850 | $955,363,980 |
| Tangible Book Value | $781,964,000 | $779,660,000 | $1,037,192,000 | $1,370,297,000 |
| Invested Capital | $972,609,000 | $796,118,000 | $1,045,595,000 | $1,379,956,000 |
| Working Capital | $751,095,000 | $736,539,000 | $984,494,000 | $1,307,980,000 |
| Capital Lease Obligations | $21,760,000 | $15,151,000 | $20,393,000 | $15,540,000 |
| Total Capitalization | $840,898,000 | $796,118,000 | $1,045,595,000 | $1,379,956,000 |
| Treasury Stock | $20,836,000 | $20,836,000 | $11,856,000 | $4,279,000 |
| Additional Paid In Capital | $3,264,295,000 | $2,975,302,000 | $2,893,120,000 | $2,825,948,000 |
| Capital Stock | $7,000 | $6,000 | $6,000 | $6,000 |
| Common Stock | $7,000 | $6,000 | $6,000 | $6,000 |
| Non Current Deferred Revenue | $31,433,000 | $28,738,000 | $21,360,000 | $27,486,000 |
| Long Term Capital Lease Obligation | $13,712,000 | $8,047,000 | $13,343,000 | $9,613,000 |
| Current Capital Lease Obligation | $8,048,000 | $7,104,000 | $7,050,000 | $5,927,000 |
| Line Of Credit | $131,711,000 | $0 | - | - |
| Current Accrued Expenses | $46,765,000 | $58,157,000 | $44,212,000 | $45,005,000 |
| Investments And Advances | $3,115,000 | $9,220,000 | $6,431,000 | $15,605,000 |
| Net PPE | $69,475,000 | $68,689,000 | $78,771,000 | $58,280,000 |
| Accumulated Depreciation | $-37,120,000 | $-30,136,000 | $-22,064,000 | $-16,425,000 |
| Gross PPE | $106,595,000 | $98,825,000 | $100,835,000 | $74,705,000 |
| Leases | $11,306,000 | $11,371,000 | $11,300,000 | $10,432,000 |
| Construction In Progress | $25,147,000 | $24,383,000 | $25,647,000 | $12,323,000 |
| Other Properties | $68,716,000 | $61,825,000 | $62,709,000 | $50,894,000 |
| Machinery Furniture Equipment | $1,426,000 | $1,246,000 | $1,179,000 | $1,056,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $24,063,000 | $22,702,000 | $12,156,000 | $5,632,000 |
| Work In Process | $2,544,000 | $4,470,000 | $436,000 | $88,000 |
| Raw Materials | $13,268,000 | $17,655,000 | $19,029,000 | $13,231,000 |
| Other Short Term Investments | $330,000,000 | $16,300,000 | $0 | $445,000,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-276,391,000 | $-206,669,000 | $-392,626,000 | $-568,179,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-214,869,000 | $-198,178,000 | $-367,642,000 | $-549,231,000 |
| Cash Flow From Continuing Operating Activities | $-214,869,000 | $-198,178,000 | $-367,642,000 | $-549,231,000 |
| Operating Gains Losses | $21,695,000 | $1,812,000 | $66,136,000 | $5,024,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-61,522,000 | $-8,491,000 | $-24,984,000 | $-18,948,000 |
| Investing Cash Flow | $-375,193,000 | $-10,776,000 | $420,016,000 | $249,957,000 |
| Cash Flow From Continuing Investing Activities | $-375,193,000 | $-10,776,000 | $420,016,000 | $249,957,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $217,350,000 | $0 | $0 | $818,875,000 |
| Financing Cash Flow | $349,889,000 | $-6,433,000 | $-1,730,000 | $820,202,000 |
| Cash Flow From Continuing Financing Activities | $349,889,000 | $-6,433,000 | $-1,730,000 | $820,202,000 |
| Net Other Financing Charges | $-1,983,000 | $-8,802,000 | $-7,600,000 | $-6,090,000 |
| Net Common Stock Issuance | $217,350,000 | $0 | $0 | $818,875,000 |
| Common Stock Issuance | $217,350,000 | $0 | $0 | $818,875,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-284,000 | $0 | $0 | $0 |
| Issuance Of Debt | $131,606,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $2,021,000 | $0 | $0 | $0 |
| End Cash Position | $550,781,000 | $791,264,000 | $1,009,273,000 | $964,903,000 |
| Beginning Cash Position | $791,264,000 | $1,009,273,000 | $964,903,000 | $442,859,000 |
| Effect Of Exchange Rate Changes | $-310,000 | $-2,622,000 | $-6,274,000 | $1,116,000 |
| Changes In Cash | $-240,173,000 | $-215,387,000 | $50,644,000 | $520,928,000 |
| Proceeds From Stock Option Exercised | $3,200,000 | $2,369,000 | $5,870,000 | $7,417,000 |
| Net Issuance Payments Of Debt | $131,322,000 | $0 | $0 | $0 |
| Net Short Term Debt Issuance | $131,322,000 | $0 | $0 | $0 |
| Short Term Debt Payments | $-284,000 | $0 | $0 | $0 |
| Short Term Debt Issuance | $131,606,000 | $0 | $0 | $0 |
| Net Investment Purchase And Sale | $-313,700,000 | $-16,300,000 | $445,000,000 | $298,902,000 |
| Sale Of Investment | $16,300,000 | $117,700,000 | $705,274,000 | $743,902,000 |
| Purchase Of Investment | $-330,000,000 | $-134,000,000 | $-260,274,000 | $-445,000,000 |
| Net Intangibles Purchase And Sale | $-55,865,000 | $8,721,000 | $-399,000 | $-653,000 |
| Sale Of Intangibles | $0 | $10,000,000 | $0 | $0 |
| Purchase Of Intangibles | $-55,865,000 | $-1,279,000 | $-399,000 | $-653,000 |
| Net PPE Purchase And Sale | $-5,628,000 | $-3,197,000 | $-24,585,000 | $-18,292,000 |
| Sale Of PPE | $29,000 | $4,015,000 | $0 | $3,000 |
| Purchase Of PPE | $-5,657,000 | $-7,212,000 | $-24,585,000 | $-18,295,000 |
| Change In Working Capital | $-68,390,000 | $39,606,000 | $-66,247,000 | $33,789,000 |
| Change In Other Working Capital | $6,588,000 | $11,181,000 | $-1,379,000 | $11,149,000 |
| Change In Other Current Liabilities | $-31,281,000 | $11,784,000 | $-1,063,000 | $24,757,000 |
| Change In Payables And Accrued Expense | $-2,209,000 | $36,803,000 | $-53,773,000 | $63,522,000 |
| Change In Payable | $-2,209,000 | $36,803,000 | $-53,773,000 | $63,522,000 |
| Change In Account Payable | $-2,209,000 | $36,803,000 | $-53,773,000 | $63,522,000 |
| Change In Prepaid Assets | $-18,804,000 | $12,433,000 | $-19,785,000 | $-7,094,000 |
| Change In Inventory | $3,896,000 | $-14,907,000 | $-15,382,000 | $-7,174,000 |
| Change In Receivables | $-26,580,000 | $-17,688,000 | $25,135,000 | $-51,371,000 |
| Changes In Account Receivables | $-26,975,000 | $-20,040,000 | $4,330,000 | $-42,319,000 |
| Other Non Cash Items | $5,599,000 | $5,325,000 | $5,748,000 | $67,848,000 |
| Stock Based Compensation | $70,651,000 | $79,634,000 | $61,302,000 | $40,714,000 |
| Provisionand Write Offof Assets | $8,000 | $6,000 | $1,000 | $10,000 |
| Asset Impairment Charge | $815,000 | $1,030,000 | $477,000 | $1,368,000 |
| Depreciation Amortization Depletion | $11,856,000 | $9,029,000 | $8,227,000 | $6,487,000 |
| Depreciation And Amortization | $11,856,000 | $9,029,000 | $8,227,000 | $6,487,000 |
| Earnings Losses From Equity Investments | $6,105,000 | $-2,789,000 | $9,173,000 | $15,674,000 |
| Net Foreign Currency Exchange Gain Loss | $15,137,000 | $14,850,000 | $56,403,000 | $-10,679,000 |
| Gain Loss On Sale Of PPE | $453,000 | $-10,249,000 | $560,000 | $29,000 |
| Net Income From Continuing Operations | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-30,000,000 |
| Purchase Of Business | - | $0 | $0 | $-30,000,000 |
| Unrealized Gain Loss On Investment Securities | - | - | $8,952,000 | $14,617,000 |